Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2), a key transcription factor regulating antioxidant, cytoprotective, and metabolic enzymes, plays important roles in drug resistance and proliferation in cancer cells. The present study was aimed to examine the expression of Nrf2 in connection with chemotherapeutic drug sensitivity on cholangiocarcinoma (CCA) cells. The basal levels of Nrf2 protein in cytosol and nuclear fractions of CCA cells were determined using Western blot analysis. Nrf2 mRNA expression of KKU-M156 and KKU-100 cells, representatives of low and high-Nrf2-expressing CCA cells, were silenced using siRNA. After knockdown of Nrf2, the sensitivity of those cells to the cytotoxicity of cisplatin (Cis) was enhanced in association with the increased release of AIF and downregulation of Bcl-xl in both cells. Also, knockdown of Nrf2 suppressed the replicative capability of those cells in colony-forming assay and enhanced their sensitivity to antiproliferative activity of Cis and 5-fluorouracil. The chemosensitizing effect was associated with the suppressed expression of Nrf2-regulated and Cis-induced antioxidant and metabolic genes including NQO1, HO-1, GCLC, TXN, MRP2, TKT, and G6PD. In cell cycle analysis, Nrf2 knockdown cells were arrested at G0/G1 phase and combination with Cis increased the accumulation of cells at S phase. The suppression of KKU-M156 cell proliferation was associated with the downregulation of cyclin D1 and increased level of p21. Inhibition of Nrf2 could be a novel strategy in enhancing antitumor activity of chemotherapeutic agent in control of resistant cancer.
Similar content being viewed by others
Abbreviations
- 5-FU:
-
5-Fluorouracil
- AO/EB:
-
Acridine orange and ethidium bromide
- CCA:
-
Cholangiocarcinoma
- Cis:
-
Cisplatin
- NT:
-
Non-target siRNA
References
Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10:77–82.
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61:1657–69.
Butthongkomvong K, Sirachainan E, Jhankumpha S, Kumdang S, Sukhontharot OU. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev. 2013;14:3565–8.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The keap1-nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45–9.
Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of nrf2. Carcinogenesis. 2008;29:1235–43.
Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008;74:1526–39.
Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the keap1-nrf2-are pathway. Annu Rev Pharmacol Toxicol. 2007;47:89–116.
Hayes JD, Dinkova-Kostova AT. The nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199–218.
Hu R, Xu C, Shen G, Jain MR, Khor TO, Gopalkrishnan A, et al. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of c57bl/6j mice and c57bl/6j/nrf2 (−/−) mice. Cancer Lett. 2006;243:170–92.
Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22:66–79.
Hayes JD, McMahon M. Nrf2 and keap1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009;34:176–88.
Ma X, Zhang J, Liu S, Huang Y, Chen B, Wang D. Nrf2 knockdown by shrna inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer. Cancer Chemother Pharmacol. 2012;69:485–94.
Lister A, Nedjadi T, Kitteringham NR, Campbell F, Costello E, Lloyd B, et al. Nrf2 is overexpressed in pancreatic cancer: Implications for cell proliferation and therapy. Mol Cancer. 2011;10:37.
Samatiwat P, Prawan A, Senggunprai L, Kukongviriyapan V: Repression of nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. Naunyn Schmiedebergs Arch Pharmacol 2015;388:601–12.
Hu XF, Yao J, Gao SG, Wang XS, Peng XQ, Yang YT, et al. Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev. 2013;14:5231–5.
Onodera Y, Motohashi H, Takagi K, Miki Y, Shibahara Y, Watanabe M, et al. Nrf2 immunolocalization in human breast cancer patients as a prognostic factor. Endocrinol Relat Cancer. 2014;21:241–52.
Yang H, Wang W, Zhang Y, Zhao J, Lin E, Gao J, et al. The role of nf-e2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer. Clin Lung Cancer. 2011;12:166–71.
Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, et al. Loss of kelch-like ech-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010;9:336–46.
Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009;15:3423–32.
Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, et al. High levels of nrf2 determine chemoresistance in type ii endometrial cancer. Cancer Res. 2010;70:5486–96.
Heiss EH, Schachner D, Zimmermann K, Dirsch VM. Glucose availability is a decisive factor for nrf2-mediated gene expression. Redox Biol. 2013;1:359–65.
Yonglitthipagon P, Pairojkul C, Chamgramol Y, Loukas A, Mulvenna J, Bethony J, et al. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol. 2012;43:1719–30.
Sripa B, Leungwattanawanit S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, et al. Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (kku-100). World J Gastroenterol. 2005;11:3392–7.
Bunthot S, Obchoei S, Kraiklang R, Pirojkul C, Wongkham S, Wongkham C. Overexpression of claudin-4 in cholangiocarcinoma tissues and its possible role in tumor metastasis. Asian Pac J Cancer Prev. 2012;13(Suppl):71–6.
Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V. Dicoumarol enhances gemcitabine-induced cytotoxicity in high nqo1-expressing cholangiocarcinoma cells. World J Gastroenterol. 2010;16:2362–70.
Suphim B, Prawan A, Kukongviriyapan U, Kongpetch S, Buranrat B, Kukongviriyapan V. Redox modulation and human bile duct cancer inhibition by curcumin. Food Chem Toxicol. 2010;48:2265–72.
Kongpetch S, Kukongviriyapan V, Prawan A, Senggunprai L, Kukongviriyapan U, Buranrat B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. PLoS One. 2012;7, e34994.
Aneknan P, Kukongviriyapan V, Prawan A, Kongpetch S, Sripa B, Senggunprai L. Luteolin arrests cell cycling, induces apoptosis and inhibits the jak/stat3 pathway in human cholangiocarcinoma cells. Asian Pac J Cancer Prev. 2014;15:5071–6.
Norberg E, Gogvadze V, Vakifahmetoglu H, Orrenius S, Zhivotovsky B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Radic Biol Med. 2010;48:791–7.
Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9.
Liu PP, Liao J, Tang ZJ, Wu WJ, Yang J, Zeng ZL, et al. Metabolic regulation of cancer cell side population by glucose through activation of the akt pathway. Cell Death Differ. 2014;21:124–35.
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11–20.
Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM, Palumbo G. Low doses of cisplatin or gemcitabine plus photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (h1299). Mol Cancer Ther. 2006;5:776–85.
Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3:1351–71.
Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin d1: normal and abnormal functions. Endocrinology. 2004;145:5439–47.
Gartel AL. P21(waf1/cip1) and cancer: a shifting paradigm? Biofactors. 2009;35:161–4.
Acknowledgments
This work was supported by the Office of the Higher Education Commission through SHeP-GMS of Khon Kaen University, grants in-aid from Khon Kaen University and Faculty of Medicine (IN58130), and a scholarship from the Royal Golden Jubilee Ph.D. Program (PS). We thank Miss S. Srichanwang of Research Affair, Faculty of Medicine, for technical assistance of flow cytometry work, Professor Y. Nawa of Publication Clinic, Khon Kaen University for English language assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. S1
Nrf2 knockdown enhanced the sensitivity of KKU-100 cells to Cis in association with altered apoptotic protein expression. The cells were transfected with siNrf2 or NT for 24 h followed by treatment with 5 μM Cis for another 18 h. Whole cell extracts were prepared for Western blotting to determine AIF, cytochrome c and Bcl-xl levels using β-actin as a loading control. (GIF 70 kb)
Rights and permissions
About this article
Cite this article
Samatiwat, P., Prawan, A., Senggunprai, L. et al. Nrf2 inhibition sensitizes cholangiocarcinoma cells to cytotoxic and antiproliferative activities of chemotherapeutic agents. Tumor Biol. 37, 11495–11507 (2016). https://doi.org/10.1007/s13277-016-5015-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-016-5015-0